Cell Signaling Technology
XP Monoclonal Antibody

Product Pathways - Cell Cycle / Checkpoint

RRM1 (D12F12) XP® Rabbit mAb #8637

Applications Reactivity Sensitivity MW (kDa) Isotype
W IHC-P IF-IC F H Mk Endogenous 90 Rabbit

Applications Key:  W=Western Blotting  IHC-P=Immunohistochemistry (Paraffin)  IF-IC=Immunofluorescence (Immunocytochemistry)  F=Flow Cytometry
Reactivity Key:  H=Human  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

* Product-specific protocol.

Specificity / Sensitivity

RRM1 (D12F12) XP® Rabbit mAb recognizes endogenous levels of total RRM1 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human RRM1 protein.

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using RRM1 (D12F12) XP® Rabbit mAb (upper) and β-Actin Antibody #4967 (lower).

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human lung carcinoma using RRM1 (D12F12) XP® Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human lymphoma using RRM1 (D12F12) XP®Rabbit mAb.


Flow Cytometry

Flow Cytometry

Flow cytometric analysis of NCI-H1703 (blue) and HeLa (green) cells using RRM1 (D12F12) XP® Rabbit mAb.

IF-IC

IF-IC

Confocal immunofluorescent analysis of HeLa (left) and XP2YO (right) cells using RRM1 (D12F12) XP® Rabbit mAb (green). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).

Background

Ribonucleotide reductase catalyzes the rate-limiting step in the synthesis of deoxynucleotide triphosphates (dNTPs). The regulatory M1 subunit (RRM1) is present throughout the cell division cycle, but downregulated in quiescent cells (1). Research studies have demonstrated that RRM1 is involved in carcinogenesis and tumor progression, and its expression is correlated with resistance to chemotherapy in non-small cell lung cancer (2-4).

  1. Mann, G.J. et al. (1988) Cancer Res 48, 5151-6.
  2. Zheng, Z. et al. (2007) N Engl J Med 356, 800-8.
  3. Ceppi, P. et al. (2006) Ann Oncol 17, 1818-25.
  4. Bepler, G. et al. (2006) J Clin Oncol 24, 4731-7.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products


For Research Use Only. Not For Use In Diagnostic Procedures.

Products